A non-conjugated peptide-adjuvant system of synthetic peptide-vaccine elicited potent antibody response and opsonic protection against clinical GAS strains

Le résumé fourni par la source

Group A Streptococcus (GAS) is a causative agent of life-threatening infections, including pharyngitis, rheumatic fever, and rheumatic heart disease. Currently, no commercial vaccines are licenced to prevent GAS infections. Synthetic peptide-based subunit vaccines composed of minimal antigenic fragments derived from the pathogenic M-protein, represent an attractive approach for mitigating GAS infection transmission. However, such small antigens are poorly immunogenic, necessitating their co-administration with strong immunostimulatory agents (adjuvants). Herein, we proposed the use of self-assembled peptides as the adjuvant by developing non-conjugated peptide-adjuvant system of GAS synthetic peptide-based vaccine in which a synthetic GAS antigen PADRE-J8 (composed of B cell epitope J8 and the universal T-helper epitope PADRE) was physically mixed with a lipopeptide TLR2 agonist (KKSS-C16-C16) and self-assembled peptides. In mice, all vaccine candidates induced antigen-specific systemic immunoglobulin G (IgG) antibodies after subcutaneous immunisation. Among them, a physical mixture of a self-assembled peptide Nap-GFFY, lipopeptide KKSS-C16-C16, and PADRE-J8 antigen (SPV-5) induced the highest antibodies production and produced antibodies were opsonic against GAS clinical isolates. The vaccine formulation lacking the lipopeptide KKSS-C16-C16 (SPV-5(-)) generated J8-specific antibodies; however, their opsonization capacity was poor, indicating that both the self-assembled peptide and the lipopeptide were essential for eliciting strong opsonic responses against bacteria.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.